Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Pullar

Showing results (61-70 of 88) with videos related to

Pageof 9
Sort By:
British Journal of Clinical Pharmacology|September 1, 1990
A comparison of a short half-life marker (low-dose isoniazid), a long half-life pharmacological indicator (low-dose phenobarbitone) and measurements of a controlled release 'therapeutic drug' (metoprolol, Metoros) in reflecting incomplete compliance by volunteersE Hardy, S Kumar, S Peaker, et al.
Annals of the Rheumatic Diseases|March 1, 1989
What should we hope to achieve when treating rheumatoid arthritis?D L Scott, T D Spector, T Pullar, et al.
British Journal of Clinical Pharmacology|February 1, 1987
N-desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy?J R Haigh, T Pullar, J P Gent, et al.
Rheumatology (Oxford, England)|June 18, 2003
Bone health in patients with fibromyalgiaA W Al-Allaf, P A Mole, C R Paterson, et al.
British Journal of Clinical Pharmacology|March 1, 1987
The effect of cimetidine on the single dose pharmacokinetics of oral clobazam and N-desmethylclobazamT Pullar, D Edwards, J R Haigh, et al.
Rheumatology (Oxford, England)|June 15, 2000
An observer-blinded comparison of supervised and unsupervised aerobic exercise regimens in fibromyalgiaC Ramsay, J Moreland, M Ho, et al.
Rheumatology (Oxford, England)|October 16, 2008
C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritisB Galarraga, F Khan, P Kumar, et al.
Scottish Medical Journal|May 5, 2012
Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled studyP Kumar, G Kennedy, F Khan, et al.
British Journal of Clinical Pharmacology|September 1, 1991
The prediction of steady-state plasma phenobarbitone concentrations (following low-dose phenobarbitone) to refine its use as an indicator of complianceT Pullar, S Kumar, H Chrystyn, et al.
Rheumatology (Oxford, England)|February 22, 2003
Rheumatoid arthritis and macrovascular diseaseJ K Alkaabi, M Ho, R Levison, et al.
Pageof 9

Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
British Journal of Clinical Pharmacology|September 1, 1990
A comparison of a short half-life marker (low-dose isoniazid), a long half-life pharmacological indicator (low-dose phenobarbitone) and measurements of a controlled release 'therapeutic drug' (metoprolol, Metoros) in reflecting incomplete compliance by volunteersE Hardy, S Kumar, S Peaker, et al.
Annals of the Rheumatic Diseases|March 1, 1989
What should we hope to achieve when treating rheumatoid arthritis?D L Scott, T D Spector, T Pullar, et al.
British Journal of Clinical Pharmacology|February 1, 1987
N-desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy?J R Haigh, T Pullar, J P Gent, et al.
Rheumatology (Oxford, England)|June 18, 2003
Bone health in patients with fibromyalgiaA W Al-Allaf, P A Mole, C R Paterson, et al.
British Journal of Clinical Pharmacology|March 1, 1987
The effect of cimetidine on the single dose pharmacokinetics of oral clobazam and N-desmethylclobazamT Pullar, D Edwards, J R Haigh, et al.
Rheumatology (Oxford, England)|June 15, 2000
An observer-blinded comparison of supervised and unsupervised aerobic exercise regimens in fibromyalgiaC Ramsay, J Moreland, M Ho, et al.
Rheumatology (Oxford, England)|October 16, 2008
C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritisB Galarraga, F Khan, P Kumar, et al.
Scottish Medical Journal|May 5, 2012
Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled studyP Kumar, G Kennedy, F Khan, et al.
British Journal of Clinical Pharmacology|September 1, 1991
The prediction of steady-state plasma phenobarbitone concentrations (following low-dose phenobarbitone) to refine its use as an indicator of complianceT Pullar, S Kumar, H Chrystyn, et al.
Rheumatology (Oxford, England)|February 22, 2003
Rheumatoid arthritis and macrovascular diseaseJ K Alkaabi, M Ho, R Levison, et al.
Pageof 9